Rep. Ro Khanna bought DexCom (DXCM)
Rep. Ro Khanna (D-CA-17) · $1K–$15K · traded Oct 2, 2023
- Transaction
- Bought
- Amount
- $1K–$15K
- Owner
- Not stated
- Traded
- Oct 2, 2023
- Disclosed
- Nov 8, 2023
- Days to disclose
- 37
- Asset type
- Stock
- As filed
- DexCom Inc
- Industry
- Medical - Devices · Healthcare
Other trades in this filing
All of Khanna's trades →- Nov 8, 2023$15K–$50K
$15K–$50K · Traded Oct 31, 2023 · disclosed Nov 8, 2023 · Spouse
- Nov 8, 2023$1K–$15K
$1K–$15K · Traded Oct 31, 2023 · disclosed Nov 8, 2023 · Spouse
- Nov 8, 2023$1K–$15K
Bought Thermo Fisher Scientific TMO
$1K–$15K · Traded Oct 31, 2023 · disclosed Nov 8, 2023 · Spouse
- Nov 8, 2023$15K–$50K
Bought Prudential Financial PRU
$15K–$50K · Traded Oct 31, 2023 · disclosed Nov 8, 2023 · Spouse
- Nov 8, 2023$1K–$15K
Sold Old Dominion Freight Line ODFL
$1K–$15K · Traded Oct 31, 2023 · disclosed Nov 8, 2023 · Spouse
- Nov 8, 2023$1K–$15K
Bought The Interpublic Group of Companies IPG
$1K–$15K · Traded Oct 31, 2023 · disclosed Nov 8, 2023 · Spouse
- Nov 8, 2023$1K–$15K
$1K–$15K · Traded Oct 31, 2023 · disclosed Nov 8, 2023 · Spouse
- Nov 8, 2023$1K–$15K
$1K–$15K · Traded Oct 31, 2023 · disclosed Nov 8, 2023 · Spouse
- Nov 8, 2023$1K–$15K
$1K–$15K · Traded Oct 31, 2023 · disclosed Nov 8, 2023 · Spouse
- Nov 8, 2023$1K–$15K
$1K–$15K · Traded Oct 31, 2023 · disclosed Nov 8, 2023 · Spouse
- Nov 8, 2023$1K–$15K
$1K–$15K · Traded Oct 31, 2023 · disclosed Nov 8, 2023 · Spouse
- Nov 8, 2023$1K–$15K
$1K–$15K · Traded Oct 31, 2023 · disclosed Nov 8, 2023 · Spouse
- Nov 8, 2023$1K–$15K
$1K–$15K · Traded Oct 31, 2023 · disclosed Nov 8, 2023 · Spouse
- Nov 8, 2023$1K–$15K
$1K–$15K · Traded Oct 31, 2023 · disclosed Nov 8, 2023 · Spouse
- Nov 8, 2023$1K–$15K
$1K–$15K · Traded Oct 31, 2023 · disclosed Nov 8, 2023 · Spouse
- Nov 8, 2023$1K–$15K
$1K–$15K · Traded Oct 31, 2023 · disclosed Nov 8, 2023 · Spouse
- Nov 8, 2023$1K–$15K
$1K–$15K · Traded Oct 31, 2023 · disclosed Nov 8, 2023 · Spouse
- Nov 8, 2023$1K–$15K
Bought Genuine Parts Company GPC
$1K–$15K · Traded Oct 31, 2023 · disclosed Nov 8, 2023 · Spouse
- Nov 8, 2023$1K–$15K
Bought Fidelity National Information Services FIS
$1K–$15K · Traded Oct 31, 2023 · disclosed Nov 8, 2023 · Spouse
- Nov 8, 2023$50K–$100K
$50K–$100K · Traded Oct 31, 2023 · disclosed Nov 8, 2023 · Spouse
Recent Congress trades in DXCM
- May 11, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
$1K–$15K · Traded Apr 13, 2026 · disclosed May 11, 2026 · Spouse
- May 10, 2026$100K–$250K
Sen. Tina Smith (D-MN)
$100K–$250K · Traded May 7, 2026 · disclosed May 10, 2026 · Spouse
- May 10, 2026$100K–$250K
Sen. Tina Smith (D-MN)
$100K–$250K · Traded Apr 29, 2026 · disclosed May 10, 2026 · Spouse
- Feb 15, 2026$1K–$15K
Sen. John Boozman (R-AR)
$1K–$15K · Traded Jan 26, 2026 · disclosed Feb 15, 2026 · Joint
- Feb 6, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
$1K–$15K · Traded Jan 29, 2026 · disclosed Feb 6, 2026 · Spouse
- Jun 22, 2025$15K–$50K
Rep. Jefferson Shreve (R-IN-6)
$15K–$50K · Traded May 12, 2025 · disclosed Jun 22, 2025
- Jun 22, 2025$15K–$50K
Rep. Jefferson Shreve (R-IN-6)
$15K–$50K · Traded May 8, 2025 · disclosed Jun 22, 2025
- Jun 9, 2025$1K–$15K
Rep. Robert P. Bresnahan, Jr. (R-PA-8)
$1K–$15K · Traded May 15, 2025 · disclosed Jun 9, 2025
Company context for DXCM
Recent records for the company. These may have been published before or after this trade; compare the dates before drawing a connection.
DXCM: third_quarter 2026 lobbying report
General representation. Legislative and regulatory issues related to policies and payments for continuous glucose monitoring
Public: Oct 20, 2026, 1:07 PM EDTOriginal source ↗DXCM: third_quarter 2026 lobbying report
Issues related to global supply chains Issues related to the Administration's Executive Orders CGM Coverage policy Issues related to sterilization of medical devices Issues related to medical device electronic labeling H.R.1539, Medical Device Electronic Labeling Act Issues related to artificial intelligence and other machine learning advances in healthcare Issues related to advances in diabetes technology Issues related to CY 2026 rulemaking CGM Coverage policies Issues related to breakthrough technology
Public: Oct 20, 2026, 11:00 AM EDTOriginal source ↗DXCM: third_quarter 2026 lobbying report
Issues related to coverage and reimbursement for continuous glucose monitors. Issues related to coverage and reimbursement for continuous glucose monitors.
Public: Oct 20, 2026, 10:03 AM EDTOriginal source ↗
From a periodic transaction report filed under the STOCK Act. Amounts are the ranges members report. Nothing here is investment advice.